Issue 27
Get instant access to latest e-book

latest news


Jul 2017

Takeda and Schrödinger Announce Multi-Year, Multi-Target Research Collaboration

Takeda Pharmaceutical Company Limited and Schrdinger Inc a privatelyheld company dedicated to revolutionizing drug discovery through advanced computational methods today announced the formation of a multitarget research collaboration directed to diseases that align with Takedas core therapeutic areas of interest The unique collaboration will combine…


Jul 2017

Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole)

Pfizer Inc and Basilea Pharmaceutica Ltd an international biopharmaceutical company specializing in the research and development of antiinfective and oncological medicines today announced they have completed the licensing agreement whereby Pfizer has obtained the exclusive commercialization rights in Europe to CRESEMBA isavuconazole a novel antifungal…


Jul 2017

ModGene Pharma Announces Issuance of US Patent for Alzheimer's Disease Prevention

ModGene Pharma LLC today announced the issuance of US Patent entitled Compositions and Methods for Reduction of Amyloidbeta Load The claims cover the use of an imatinibrelated compound for reduction of amyloid production in Alzheimers disease The compound imatinib paradiaminomethylbenzene trihydrochloride is threefold more potent…

press releases


Jul 2017

Philogen Enters into Multi-Target Research Agreement with Boehringer Ingelheim in the Field Of DNA-Encoded Chemistry

Philogen SpA a privately owned biotechnology company today announced a collaboration and license agreement with Boehringer Ingelheim to discover and optimize novel small moleculebased therapeutics using Philochems proprietary Encoded SelfAssembling…


Jul 2017

Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue™ (insulin glargine injection), a Follow-On Biologic Basal Insulin

Merck known as MSD outside of the United States and Canada today announced that the US Food and Drug Administration FDA has granted tentative approval for LUSDUNA Nexvue insulin glargine…


Jul 2017

SillaJen and Lee\'s Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

SEOUL Korea andSAN FRANCISCO andHONG KONG July PRNewswire SillaJen Inc KOSDAQ a clinicalstage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer and Lees Pharmaceutical Holdings Ltd…

Events


Jul 2017

World Congress on Nursing Care 2017

Conference Series LLC


  • 4

    Parenteral Preparations

    INTRODUCTION Parenteral preparations are defined as solutions suspensionsemulsions for injection or infusion powders for injection or infusion gels for injecti..

Knowledge Bank

  • Interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen PhD is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging He frequently presents on international conferences on subjects related to elastomeric and aluminiumplastic closures for pharmaceutical applications Re..

  • Articles

    Antimicrobial Stewardship Prioritising Quality Access to Healthcare

    Antimicrobials treatments that kill or inhibit the growth of microorganisms are effective and necessary in medicine However organisms and microbes have increasingly begun to resist antimicrobial agents through evolutionary change and mutations Resistance to antimicrobials creates a difficult path for infectious disease medicine because it becomes harder and harder to treat resistant microbes While…

  • Techno Trends

    FDA Approves Novartis Kisqali® Femara® Co-Pack to treat metastatic breast cancer

    Novartis has announced that its Kisqali Femara CoPack the first and only currently available combination pack with two prescription products in advanced breast cancer has received approval from the US Food and Drug Administration FDA The Kisqali Femara CoPack ribociclib tablets letrozole tablets is used to treat hormone receptorpositive human epidermal growth factor receptor negative HR HER advanced or metastatic…

Editorial Section

  • Strategy

    Failing Data Integrity Audit is not an Option

    The timetomarket of blooming Asian pharmaceutical companies especially from India and China are being slowed by the increasing concerns of global and local regulators over data integrity How can they meet regulators audit expectation on data integrity and provide assurance…

  • Clinical Trails

    Patient Recruitment

    To address the challenges faced in patient recruitment and retention in clinical trials innovative technologies are being utilised in AsiaPacific as well as other regions to optimise the processes involved From patient matching to improving the consent process technology has…

  • Manufacturing

    Added Costs for Added Protections

    The Impact of Implementing Safety Features in Pharmaceutical Packaging and Labelling Serialization Unique Device Identification UDI and aggregation catalyse a paradigm shift for the entire industry and are already impacting the pharmaceutical supply chain In…

  • Expert Talk

    The Asian Healthcare Market

    The Asian market is growing rapidly and along with this expansion comes the issue of drug counterfeiting Bernd offers his insight into the key trends affecting this market and what regulatory authorities are expecting manufacturers…